Back to Search Start Over

Near-infrared II fluorescence-guided glioblastoma surgery targeting monocarboxylate transporter 4 combined with photothermal therapy.

Authors :
Zhao H
Li C
Shi X
Zhang J
Jia X
Hu Z
Gao Y
Tian J
Source :
EBioMedicine [EBioMedicine] 2024 Aug; Vol. 106, pp. 105243. Date of Electronic Publication: 2024 Jul 13.
Publication Year :
2024

Abstract

Background: Surgery is crucial for glioma treatment, but achieving complete tumour removal remains challenging. We evaluated the effectiveness of a probe targeting monocarboxylate transporter 4 (MCT4) in recognising gliomas, and of near-infrared window II (NIR-II) fluorescent molecular imaging and photothermal therapy as treatment strategies.<br />Methods: We combined an MCT4-specific monoclonal antibody with indocyanine green to create the probe. An orthotopic mouse model and a transwell model were used to evaluate its ability to guide tumour resection using NIR-II fluorescence and to penetrate the blood-brain barrier (BBB), respectively. A subcutaneous tumour model was established to confirm photothermal therapy efficacy. Probe specificity was assessed in brain tissue from mice and humans. Finally, probe effectiveness in photothermal therapy was investigated.<br />Findings: MCT4 was differentially expressed in tumour and normal brain tissue. The designed probe exhibited precise tumour targeting. Tumour imaging was precise, with a signal-to-background (SBR) ratio of 2.8. Residual tumour cells were absent from brain tissue postoperatively (SBR: 6.3). The probe exhibited robust penetration of the BBB. Moreover, the probe increased the tumour temperature to 50 °C within 5 min of laser excitation. Photothermal therapy significantly reduced tumour volume and extended survival time in mice without damage to vital organs.<br />Interpretation: These findings highlight the potential efficacy of our probe for fluorescence-guided surgery and therapeutic interventions.<br />Funding: Jilin Province Department of Science and Technology (20200403079SF), Department of Finance (2021SCZ06) and Development and Reform Commission (20200601002JC); National Natural Science Foundation of China (92059207, 92359301, 62027901, 81930053, 81227901, U21A20386); and CAS Youth Interdisciplinary Team (JCTD-2021-08).<br />Competing Interests: Declaration of interests The authors declare that they have no conflicts of interest.<br /> (Copyright © 2024. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
2352-3964
Volume :
106
Database :
MEDLINE
Journal :
EBioMedicine
Publication Type :
Academic Journal
Accession number :
39004066
Full Text :
https://doi.org/10.1016/j.ebiom.2024.105243